THE ARISING · Longevity & Healthspan
ACOG Updates Hormonal and Nonhormonal Options for Menopause Symptoms
The guideline separates the treatment of hot flashes and related sleep disruption from the treatment of depression.
Hot flashes, night sweats, broken sleep and low mood can overlap around menopause. A new American College of Obstetricians and Gynecologists guideline helps clinicians and patients sort out which symptoms to treat first, and which options fit their risks and preferences. The guideline covers symptoms related to spontaneous menopause or menopause induced at age 40 or older.
This is a clinical practice guideline, not a new treatment trial. ACOG's writing team reviewed the evidence and graded the strength and certainty of its recommendations. Where there was too little evidence to make a formal recommendation, the guideline offered practical advice separately.
For bothersome hot flashes and sleep disruption linked to them, hormone therapy is one option. When a patient and clinician select it and no contraindications are present, ACOG recommends beginning before age 60 or within 10 years of the start of natural menopause. That timing is not a reason to start therapy on its own. Decisions should also consider symptoms, medical history, baseline risk of cardiovascular disease, breast cancer and blood clots, and the patient's goals. Decisions about when to stop are individualized too.
The advice is different when depression is the main concern. ACOG found insufficient evidence to recommend for or against systemic hormone therapy for menopause-related depressive symptoms. When depression predominates or a patient meets criteria for major depression, ACOG advises treating it according to depression-management guidelines.
Nonhormonal choices for hot flashes include drugs that act on neurokinin receptors, such as fezolinetant and elinzanetant, and some antidepressants. Nonhormonal does not mean risk-free: fezolinetant carries an FDA boxed warning for rare but serious liver injury and requires liver testing before and during treatment. Recommendations for nondrug options, including cognitive behavioral therapy, exercise and clinical hypnosis, differ by symptom and by how strong the evidence is. ACOG did not find convincing evidence to recommend phytoestrogen or herbal supplements for these symptoms.
The practical change is a more specific clinical conversation: name which symptom is disrupting daily life, weigh the choices and agree on how to judge whether treatment is helping. This guidance is about symptom relief, not prescribing hormones to prevent chronic disease. ACOG is developing separate guidance for genitourinary symptoms of menopause.